Muutke küpsiste eelistusi

E-raamat: IgA Nephropathy Today

Series edited by , Edited by
  • Formaat - PDF+DRM
  • Hind: 251,16 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Primary IgA nephropathy has first been described as a new disease entity almost 40 years ago. This disorder, considered to be an immune-complex-mediated glomerulonephritis, is characterized by granular deposition of IgA (mainly IgA1) and C3 in the glomerular mesangial areas and is defined as nephropathy showing proliferative changes in the glomerular mesangial cells and increases in the mesangial matrices. Apart from being one of the most common types of chronic glomerulonephritis, it is also the most frequent case of end-stage renal disease. But even though continuing efforts have gradually clarified various aspects of the pathogenesis of the disease, specific treatment is not yet available. In this publication, international nephrologists and basic scientists report the most recent data on IgA nephropathy. Starting with clinical reviews on topics such as the clinico-pathological classification, new treatment approaches, and the role of renal biopsies, the focus then shifts towards basic reviews on, for example, candidate genes, the pathogenic role of IgA receptors or immune complex formation. Updates on clinical and basic advances, discussing among other things the influence of obesity or various therapeutic approaches, make up the second part of the book. Presenting up-to-date information on this still mysterious disease, the publication at hand constitutes a valuable source of information for nephrologists, general practitioners, residents and interns.
Foreword ix
Tomino, Y.
Chairman's Reviews
Pathogenesis of IgA Nephropathy
1(7)
Tomino, Y.
Treatment for IgA Nephropathy
8(5)
Tomino, Y.
Clinical Reviews of IgA Nephropathy
International IgA Nephropathy Network Clinico-Pathological Classification of IgA Nephropathy
13(6)
Feehally, J.
Barratt, J.
Coppo, R.
Cook, T.
Roberts, I.
IgA Nephropathy: A Clinical Overview
19(8)
Julian, B.A.
Wyatt, R.J.
Matousovic, K.
Moldoveanu, Z.
Mestecky, J.
Novak, J.
Angiotensin Antagonists and Fish Oil for Treating IgA Nephropathy
27(10)
Coppo, R.
Amore, A.
Peruzzi, L.
Mancuso, D.
Camilla, R.
Treatment of IgA Nephropathy: Corticosteroids, Tonsillectomy, and Mycophenolate Mofetil
37(7)
Kawamura, T.
Interpretation of Renal Biopsies in IgA Nephropathy
44(6)
Cook, H.T.
Basic Reviews of IgA Nephropathy
Altered Expression of Lymphocyte Homing Chemokines in the Pathogenesis of IgA Nephropathy
50(6)
Buren, M.
Yamashita, M.
Suzuki, M.
Tomino, Y.
Emancipator, S.N.
IgA Nephropathy: Current Views of Immune Complex Formation
56(8)
Mestecky, J.
Suzuki, H.
Yanagihara, T.
Moldoveanu, Z.
Tomana, M.
Matousovic, K.
Julian, B.A.
Novak, J.
Pathogenic Role of IgA Receptors in IgA Nephropathy
64(6)
Monteiro, R.C.
The Mucosa-Bone-Marrow Axis in IgA Nephropathy
70(10)
Suzuki, Y.
Tomino, Y.
Searching for IgA Nephropathy Candidate Genes: Genetic Studies Combined with High Throughput Innovative Investigations
80(10)
Schena, F.P.
Cerullo, G.
Torres, D.D.
Zaza, G.
Cox, S.
Bisceglia, L.
Scolari, F.
Frasca, G.
Ghiggeri, G.M.
Amoroso, A.
Clinical Advances (Update)
Clinicopathological Influence of Obesity in IgA Nephropathy: Comparative Study of 74 Patients
90(4)
Tanaka, M.
Tsujii, T.
Komiya, T.
Iwasaki, Y.
Sugishita, T.
Yonemoto, S.
Tsukamoto, T
Fukui, S.
Takasu, A.
Muso, E.
A Multicenter Prospective Cohort Study of Tonsillectomy and Steroid Therapy in Japanese Patients with IgA Nephropathy: A 5-Year Report
94(5)
Miyazaki, M.
Hotta, O.
Komatsuda, A.
Nakai, S.
Shoji, T.
Yasunaga, C.
Taguma, Y.
Tonsillectomy and Corticosteroid Therapy with Concomitant Methylprednisolone Pulse Therapy for IgA Nephropathy
99(5)
Suwabe, T.
Ubara, Y.
Sogawa, Y.
Higa, Y.
Nomura, K.
Nakanishi, S.
Hoshino, J.
Sawa, N.
Katori, H.
Takemoto, F.
Kara, S.
Ohashi, K.
Takaichi, K.
Impact of Annual Urine Health Check-Up System to Obtain Clinical Remission in Patients with IgA Nephropathy
104(5)
Ieiri, N.
Hotta, O.
Taguma, Y.
Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy
109(5)
Rasche, F.M.
Keller, F.
von Muller, L.
Czock, D.
Lepper, P.M.
Prospective Trial of Combined Therapy with Heparin/Warfarin and Renin-Angiotensin System Inhibitors in Progressive IgA Nephropathy
114(6)
Ishii, T.
Kawamura, T.
Tsuboi, N.
Ogura, M.
Utsunomiya, Y.
Hosoya, T.
Basic Advances (Update)
Downregulation of the β1,3-Galactosyltransferase Gene in Tonsillar B Lymphocytes and Aberrant Lectin Bindings to Tonsillar IgA as a Pathogenesis of IgA Nephropathy
120(5)
Inoue, T.
Sugiyama, P.
Kikumoto, Y
Fukuoka, N.
Maeshima, Y
Hattori, P
Fukushima, K.
Nishizaki, K.
Hiki, Y.
Makino, H.
Development of IgA Nephropathy-Like Disease with High Serum IgA Levels and Increased Proportion of Polymeric IgA in β1,4-Galactosyltransferase-Deficient Mice
125(4)
Nishie, T.
Miyaishi, O.
Azuma, H.
Kameyama, A.
Naruse, C.
Hashimoto, N.
Yokoyama, H.
Narimatsu, H.
Wada, T.
Asano, M.
IgA Nephropathy: Characterization of IgG Antibodies Specific for Galactose-Deficient IgA1
129(5)
Suzuki, H.
Moldoveanu, Z.
Hall, S.
Brown, R.
Julian, B.A.
Wyatt, R.J.
Tomana, M.
Tomino, Y.
Novak, J.
Mestecky, J.
IgA Nephropathy and Henoch-Schoenlein Purpura Nephritis: Aberrant Glycosylation of IgA1, Formation of IgA1-Containing Immune Complexes, and Activation of Mesangial Cells
134(5)
Novak, J.
Moldoveanu, Z.
Renfrow, M.B.
Yanagihara, T.
Suzuki, H.
Raska, M.
Hall, S.
Brown, R.
Huang, W.-Q.
Goepfert, A.
Kilian, M.
Poulsen, K.
Tomana, M.
Wyatt, R.J.
Julian, B.A.
Mestecky, J.
Patients with IgA Nephropathy Respond Strongly Through Production of IgA with Low Avidity Against Staphylococcus aureus
139(5)
Shimizu, Y.
Seki, M.
Kaneko, S.
Hagiwara, M.
Yoh, K.
Yamagata, K.
Koyama, A.
Transferrin Receptor Engagement by Polymeric IgA1 Induces Receptor Expression and Mesangial Cell Proliferation: Role in IgA Nephropathy
144(4)
Tamouza, H.
Vende, F.
Tiwari, M.
Arcos-Fajardo, M.
Vrtovsnik, F.
Benhamou, M.
Monteiro, R.C.
Moura, I.C.
IgA Fc Receptor I Is a Molecular Switch that Determines IgA Activating or Inhibitory Functions
148(5)
Kanamaru, Y.
Blank, U.
Monteiro, R.C.
The Role of PDGF-D in Mesangioproliferative Glomerulonephritis
153(6)
Floege, J.
van Roeyen, C.
Boor, P.
Ostendorf, T.
Analysis of Innate Immune Responses in a Model of IgA Nephropathy Induced by Sendai Virus
159(5)
Yamashita, M.
Chintalacharuvu, S.R.
Kobayashi, N.
Nedrud, J.G.
Lamm, M.E.
Tomino, Y.
Emancipator, S.N.
Roles of Bone Marrow, Mucosa and Lymphoid Tissues in Pathogenesis of Murine IgA Nephropathy
164(5)
Aizawa, M.
Suzuki, Y.
Suzuki, H.
Pang, H.
Kihara, M.
Yamaji, K.
Horikoshi, S.
Tomino, Y.
Concluding Remarks
169(75)
Glassock, R.J.
Abstracts
Clinical Reviews of IgA Nephropathy
174(6)
Basic Reviews of IgA Nephropathy
180(5)
Clinical Advances (Update)
185(30)
Basic Advances (Update)
215(28)
Closing Remarks
243(1)
Author Index 244(5)
Subject Index 249